~ Richard S. Kollender Appointed to Chief Operating Officer ~ ~ Robert Lutz Promoted to Chief Financial Officer ~ ~ David Gill Appointed to Board of Directors ~ DUBLIN, Ireland and TREVOSE, Pa., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Strongbridge Biopharma plc, (Nasdaq: S... read more

Conference Call & Webcast Scheduled for Wednesday, August 14, at 8:30am Eastern Time GAITHERSBURG, Md., Aug. 13, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc.(Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced financial results for the three and six months ended June 30, 2... read more

Oslo, Norway, 12 August 2019 – Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, will announce its second quarter and first half 2019 results on Thursday, 22 August 2019. A presentation by Targovax’s manageme... read more

BOSTON and STOCKHOLM, Aug. 5, 2019 /PRNewswire/ -- Aprea Therapeutics, a clinical-stage biotechnology company focused on developing and commercializing novel cancer therapeutics that reactivate mutant p53 tumor suppressor protein, today announced the appointment of Scott Coiante as Senior Vice... read more

GAITHERSBURG, Md., Aug. 05, 2019 (GLOBE NEWSWIRE) -- Altimmune, Inc.(Nasdaq: ALT), a clinical stage biopharmaceutical company focused on developing liver disease and immune modulating therapies, today announced that it will report financial results for the three and six months ended June 30, 201... read more